Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Eli Lilly & Co. gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease drug helped slow the decline of cognition and daily function in patients with early forms of the disease when compared to those taking a placebo. Donanemab, an antibody-based treatment, targets the N3pG beta amyloid; it is currently being tested in a Phase 2 clinical trial, and Lilly said it expects to share full data from the study in the future.

Lilly's stock jumps 15% after experimental Alzheimer's drug shows it can slow cognitive decline

INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease...

Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial

argenx

EyePoint Pharmaceuticals

Gilead Sciences

Gracell Biotechnologies

Inovio Pharmaceuticals

Paratek Pharma

Zai Lab Ltd.

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

Alibaba

Goldman Sachs

Mastercard

Peloton

Spiros Segalas (Trades, Portfolio) has revealed his portfolio for the fourth quarter, which ended Oct. 31, 2020, earlier this week. His top trades included reductions in Mastercard Inc. (NYSE:MA), Goldman Sachs Group Inc. (NYSE:GS) and Alibaba Group Holding Ltd.

Spiros Segalas' Top Trades of the 4th Quarter

Mondelez

Marathon Petroleum

Norfolk Southern

Raytheon Technologies

We finally made it: 2021 is here. Hopefully, many of the issues that were difficult in 2020 will start to fade this year as the country returns to a more normal status.

5 Goldman Sachs Conviction List Dividend Stocks to Buy for 2021

AbbVie

Abbott Labs

Novo Nordisk

Thermo Fisher Scientific

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.

5 Health Care Stocks Outperforming the Benchmark

ABM Industries

Acme United

Amgen

Balchem

Franklin Resources

City Hld

Ensign Group

Washington Trust Bancorp

This weekly article series covers dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Changes: December 12-18, 2020

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.

Here's Why Lilly (LLY) Has Outperformed the Industry This Year

Darden Restaurants

Dividend increases, which were very rare early in the pandemic as plenty of firms cut or suspended their payouts, have become more frequent as 2020 has gone along.

Eli Lilly, Amgen, and 2 Other Companies That Raised Their Dividends This Week

INDIANAPOLIS, Dec. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico. Conducting the...

Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

Broadcom

This is an exciting time for dividend growth investors as it seems companies of all sizes and industries are announcing dividend increases. We will highlight three large companies that have provided their shareholders with at least a 10% dividend increase in recent weeks.

3 Stocks Delivering Over 10% Dividend Increases

Prevail Therapeutics Inc

This week, Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) announced a definitive agreement for Lilly to acquire Prevail for up to $1.04 billion. These are the details.

Why Eli Lilly (LLY) Is Buying Prevail Therapeutics (PRVL) For Up To $1.04 Billion

NEW ORLEANS, Dec. 16, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Prevail Therapeutics Inc. (NasdaqGS: PRVL) to Eli Lilly and Company (NYSE: LLY). Under the...

PREVAIL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prevail Therapeutics Inc. - PRVL

Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.

Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies

Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.

Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance

BioMarin Pharmaceutical

Bristol-Myers

McKesson

Regeneron Pharmaceuticals

With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.

Goldman Sachs Adds Pharmaceutical Giant to Conviction List of Top Stocks to Buy

Eli Lilly and Company (LLY) CEO Dave Ricks on 2021 Guidance/Update Results - Earnings Call Transcript

On Tuesday morning, drugmaker Eli Lilly & Co. (NYSE:LLY) announced that it plans to purchase Prevail Therapeutics Inc. (NASDAQ:PRVL), a gene therapy developer, in an all-cash deal that values the acquisition at $1.04 billion, or $22.50 per share, representing an 80% premium to Monday's closing price.

Eli Lilly to Prevail With Prevail Therapeutics

Eli Lilly and Co. (NYSE:LLY) shareholders got an early Christmas gift Tuesday when shares of the Indianapolis-based pharma giant climbed more than 6% to $167.43. The company had plenty of cheer to spread around, announcing it received two Food and Drug Administration emergency use authorizations for Covid-19 therapeutics that will add between $1 billion and $2 billion in sales this year alone.

Christmas Came Early for Eli Lilly Shareholders

The big drugmaker upped its guidance for this year and announced a bullish outlook for 2021.

Why Eli Lilly Stock Jumped Today

The buyer is also on the hook for a milestone payment that could hit $4 per share.

Eli Lilly Acquiring Prevail Therapeutics in $880 Million Deal

Eli Lilly & Co. (NYSE: LLY) expressed plans of acquiring Prevail Therapeutics Inc. (NASDAQ: PRVL) on Tuesday for £770 million – a move that it says will help it expand its footprint in gene therapy. Lilly announced a 15% increase in quarterly dividend earlier this week.

Eli Lilly to acquire gene therapy specialist Prevail Therapeutics for £770 million

Mesoblast

Anavex Life Sciences

BioNTech SE

vTv Therapeutics

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal year 2020 EPS and sales guidance above analyst estimates.

Why Mesoblast, Anavex And More Pharma Stocks Are Moving Today

Lilly announced plans to acquire the small biotech.

Why Prevail Therapeutics Stock Is Skyrocketing Today

Eli Lilly agreed to buy gene therapy company Prevail Therapeutics for $1.04 billion on Tuesday, sending PRVL stock to a record high. The deal is worth $880 million up front and a CVR.

News for Eli Lilly Stock (LLY)